Menu
Back to Archived Journals » Core Evidence » Volume 8
Lixivaptan – an evidence-based review of its clinical potential in the treatment of hyponatremia
Received 13 May 2013
Accepted for publication 10 June 2013
Published 11 July 2013 Volume 2013:8 Pages 47—56
DOI https://doi.org/10.2147/CE.S36744
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Brendan T Bowman, Mitchell H Rosner
Division of Nephrology, University of Virginia Health System, Charlottesville, VA, USA
Abstract: Hyponatremia is the most common electrolyte abnormality seen in clinical practice. Most cases of euvolemic or hypervolemic hyponatremia involve arginine vasopressin (AVP). AVP leads to a concentrated urine and negative free water clearance. Given this primary role of AVP, antagonizing its effect through blockade of its receptor in the distal tubule is an attractive therapeutic target. Lixivaptan is a newer, non-peptide, vasopressin type 2 receptor antagonist. Recent studies have demonstrated efficacy. This review summarizes the clinical pharmacology and data for this new agent.
Keywords: vasopressin, hyponatremia, heart failure, lixivaptan, therapy, outcomes
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.